Law report No. GLW-7644 · filed November 19, 2026
Regulation & EnforcementReported case
FDA Warning Letter Targets Alkem Plant Generating 45% of US Revenue
The FDA’s November 18, 2026 warning letter targets Alkem’s Amaliya, Daman plant, which generates 45% of the company’s US revenue. Shipments continue, but new approvals face risk.
By Amara Osei5 min read905 words
Holding
- The FDA warning letter, dated November 18, 2026, targets Alkem’s Amaliya, Daman facility.
- Daman accounts for 45% of Alkem’s revenue generated in the United States.
- Alkem plans to submit its response within 15 working days.
- The FDA audited Daman from April 20 through May 1, 2026, and Alkem disclosed the OAI classification in August.
- Pithampur received two procedural observations on Form 483 following a July 2026 FDA audit.

By Amara Osei
The US Food and Drug Administration issued a warning letter dated November 18, 2026, for Alkem Laboratories’ manufacturing facility at Amaliya, Daman, a site the company says generates 45% of its revenue from the United States.
What did the FDA decide?
The action followed an inspection whose status the FDA classified as “Official Action Indicated,” according to the source alert. Alkem disclosed that classification in August 2026 after the agency audited the facility from April 20 through May 1, 2026.
The supplied report does not reproduce the warning letter or identify the deficiencies cited in it. It establishes the regulatory status and chronology, but not the precise grounds for action. That distinction matters when clients assess what an untested market assumption looks like in regulatory form.
Alkem said it would submit a comprehensive response within the FDA’s allowed period. SAHI’s alert puts that period at 15 working days. The company also said it continues to manufacture approved products at Daman and export existing approved products from the site.
Takeaway: Existing shipments remain active, while the formal escalation puts the plant on a remediation clock.
What does the warning letter change?
Under the sequence described by SAHI, escalation from “Official Action Indicated” to a warning letter generally freezes new product approvals for the affected unit. The manufacturer must complete corrective and preventive action and obtain a satisfactory reinspection before the matter resolves.
That sequence does not automatically stop sales of already approved formulations. SAHI said current shipments of previously approved formulations “remain unaffected.” The sharper commercial exposure sits in the pipeline: pending generic approvals, including ANDAs linked to the site, may face delays or holds.
For practitioners, the immediate task is to map every US-facing product, application and manufacturing dependency to Amaliya. Teams should distinguish approved inventory already in commerce from new approvals that the warning letter could constrain. Counsel and investors will then watch Alkem’s response, FDA updates on linked ANDAs, and any import-alert reclassification or follow-up inspection timeline.
SAHI called Daman a flagship US export facility vital to international operations. Its assessment identified operational and margin headwinds, near- to medium-term compliance and pipeline bottlenecks, a bearish market bias and an underweight recommendation for pharmaceutical exporters and US generic formulations over a three-to-12-month horizon.
SAHI said the escalation “typically blocks new drug approvals from the site.” It also reported that US FDA oversight of overseas pharmaceutical manufacturing has intensified. Daman now sits within a broader enforcement pattern, not an isolated administrative wrinkle.
Takeaway: The letter protects near-term supply more effectively than it protects the plant’s future US product pipeline.
What happened at Daman and Pithampur?
The warning letter followed Alkem’s own earlier disclosure. Alkem reported the “Official Action Indicated” classification in August after the April and May audit, and the FDA escalated the matter on November 18.
In the same month, Alkem reported two procedural observations on Form 483 for its Pithampur facility following a US FDA audit conducted in July 2026. The source does not link the Pithampur observations to the Daman warning letter or say that the two facilities share a remediation plan.
One plant advanced to a warning letter. The other generated two observations. Different files. Different risks.
Takeaway: Daman has escalated further, while Pithampur remains a separate compliance thread.
What should lawyers and compliance teams watch?
The first formal milestone identified by SAHI is Alkem’s response due within 15 working days. The company says it will use that filing to present a comprehensive response, although the source does not describe its contents. A submission starts the FDA’s review; it does not itself satisfy the agency.
The agency may then update the regulatory status of pending ANDAs linked to Daman, announce a follow-up inspection timeline or move toward an import alert if remediation proves inadequate. SAHI identifies those as potential trigger factors, not outcomes already recorded in the warning-letter alert.
The likely financial consequences include delayed generic approvals, higher compliance overheads and remediation costs that weigh on margins. SAHI also flagged possible import-alert escalation if the FDA finds corrective measures inadequate.
Existing approved-product shipments provide a buffer, but they do not remove medium-term risk. SAHI described resolution of the warning letter as a critical trigger for stabilizing earnings expectations and restoring investor confidence. Its market view therefore depends less on whether Daman can keep making approved products than on whether it can regain clearance for new ones.
Takeaway: The next regulatory update will carry more weight than another assurance about current production.
How should readers treat the 45% figure?
The 45% figure refers to the Daman facility’s share of Alkem’s revenue generated in the United States, as stated in the source alert. It is not an independently verified estimate of the plant’s share of companywide revenue, which the alert puts at about 9.2%.
The percentages use different denominators: 45% measures exposure within US revenue, while 9.2% measures the claimed plant share across Alkem’s total revenue. The source does not independently verify the latter estimate.
For readers assessing exposure, the useful distinction is simple: Daman has substantial leverage over US-facing revenue but a smaller stated claim on total company revenue. US generic pipelines and exports remain the sensitive part.
Takeaway: Read 45% as a US-market exposure figure, not a companywide plant share.
via sahi.com (Source)
More from Amara Osei
Show full bio
Senior reporter covering people, launches and day-to-day practice in International law and legal practice at Global Law Wire.
351 articles
Also before the court
- FDA Classifies Wanbury’s Tanuku API Plant OAI in November 2026
- FDA Hits Caplin Steriles Plant With OAI Status After 10 Observations
- FTC Warns 25 Healthcare Marketers Over Deceptive Plan Practices
- Sudeep Pharma Poicha unit faces closure over pipeline, storage flaws
- FCA Finalises UK Disclosure Rules Aligned to SRS for Listings